Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected ObsEva SA (NASDAQ: OBSV) for due-diligence and potential coverage as ...

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted to recommend marketing authorization for Imraldi (adalimumab, Samsung Bioepsis UK Limited) ...

BAAR, Switzerland, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Samsung Bioepis Co. Ltd, a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European launch of IMRALDI TM, an ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Imraldi (also known as SB5), an adalimumab biosimilar candidate ...

Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...

IMRALDI has been developed by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen (NASDAQ, BIIB) and is approved for the treatment of rheumatoid arthritis (RA), juvenile idiopathic ...

OpenAI is planning its biggest ChatGPT overhaul yet, aiming ‌to turn it into a "superapp" with coding tools and AI agents to boost revenue ⁠ahead of a planned share listing, the Financial Times ...